The filing is an amendment (10-K/A) to the previously filed 2025 Annual Report. The primary purpose is to correct immaterial errors in Management's Discussion and Analysis (MD&A) and to include required Part III governance and compensation disclosures. The company has undergone a significant strategic shift, divesting legacy subsidiaries (IPS, Softell, Bonum Health) to focus exclusively on its specialty pharmaceutical subsidiary, Scienture LLC. Revenue for 2025 was $431,609, driven by the launch of ARBLI, compared to $136,643 in 2024. The company reported a net loss of $41.5 million for 2025, heavily impacted by $26.3 million in non-cash impairment charges. Working capital improved to approximately $5.2 million as of December 31, 2025, from a deficit of $1.6 million in the prior year.